Global Aesthetics Consensus: Botulinum Toxin Type A--Evidence-Based Review, Emerging Concepts, and Consensus Recommendations for Aesthetic Use, Including Updates on Complications.
Identifieur interne : 002098 ( PubMed/Curation ); précédent : 002097; suivant : 002099Global Aesthetics Consensus: Botulinum Toxin Type A--Evidence-Based Review, Emerging Concepts, and Consensus Recommendations for Aesthetic Use, Including Updates on Complications.
Auteurs : Hema Sundaram [France] ; Massimo Signorini ; Steven Liew ; Ada R. Trindade De Almeida ; Yan Wu ; André Vieira Braz ; Steven Fagien ; Greg J. Goodman ; Gary Monheit ; Hervé RaspaldoSource :
- Plastic and reconstructive surgery [ 1529-4242 ] ; 2016.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Consensus, Facteurs de l'âge, Femelle, Guides de bonnes pratiques cliniques comme sujet, Humains, Injections sous-cutanées, Mâle, Médecine factuelle, Neurotoxines (administration et posologie), Neurotoxines (effets indésirables), Rajeunissement (physiologie), Résultat thérapeutique, Satisfaction du patient (), Sujet âgé, Techniques cosmétiques (normes), Toxines botuliniques de type A (effets indésirables), Toxines botuliniques de type A (usage thérapeutique), Vieillissement de la peau (), Évaluation des risques.
- MESH :
- administration et posologie : Neurotoxines.
- effets indésirables : Neurotoxines, Toxines botuliniques de type A.
- normes : Techniques cosmétiques.
- physiologie : Rajeunissement.
- usage thérapeutique : Toxines botuliniques de type A.
- Adulte d'âge moyen, Consensus, Facteurs de l'âge, Femelle, Guides de bonnes pratiques cliniques comme sujet, Humains, Injections sous-cutanées, Mâle, Médecine factuelle, Résultat thérapeutique, Satisfaction du patient, Sujet âgé, Vieillissement de la peau, Évaluation des risques.
English descriptors
- KwdEn :
- Age Factors, Aged, Botulinum Toxins, Type A (adverse effects), Botulinum Toxins, Type A (therapeutic use), Consensus, Cosmetic Techniques (standards), Evidence-Based Medicine, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Neurotoxins (administration & dosage), Neurotoxins (adverse effects), Patient Satisfaction (statistics & numerical data), Practice Guidelines as Topic, Rejuvenation (physiology), Risk Assessment, Skin Aging (drug effects), Treatment Outcome.
- MESH :
- chemical , administration & dosage : Neurotoxins.
- chemical , adverse effects : Botulinum Toxins, Type A, Neurotoxins.
- chemical , therapeutic use : Botulinum Toxins, Type A.
- drug effects : Skin Aging.
- physiology : Rejuvenation.
- standards : Cosmetic Techniques.
- statistics & numerical data : Patient Satisfaction.
- Age Factors, Aged, Consensus, Evidence-Based Medicine, Female, Humans, Injections, Subcutaneous, Male, Middle Aged, Practice Guidelines as Topic, Risk Assessment, Treatment Outcome.
Abstract
Botulinum toxin type A injection remains the leading nonsurgical cosmetic procedure worldwide, with a high rate of efficacy and patient satisfaction.
DOI: 10.1097/01.prs.0000475758.63709.23
PubMed: 26910696
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002124
Links to Exploration step
pubmed:26910696Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Global Aesthetics Consensus: Botulinum Toxin Type A--Evidence-Based Review, Emerging Concepts, and Consensus Recommendations for Aesthetic Use, Including Updates on Complications.</title>
<author><name sortKey="Sundaram, Hema" sort="Sundaram, Hema" uniqKey="Sundaram H" first="Hema" last="Sundaram">Hema Sundaram</name>
<affiliation wicri:level="1"><nlm:affiliation>Rockville, Md.; Milan, Italy; Sydney, New South Wales, and Carlton, Victoria, Australia; São Paolo and Rio de Janeiro, Brazil; Beijing, China; Boca Raton, Fla.; Seoul, Korea; and Cannes, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Rockville, Md.; Milan, Italy; Sydney, New South Wales, and Carlton, Victoria, Australia; São Paolo and Rio de Janeiro, Brazil; Beijing, China; Boca Raton, Fla.; Seoul, Korea; and Cannes</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Signorini, Massimo" sort="Signorini, Massimo" uniqKey="Signorini M" first="Massimo" last="Signorini">Massimo Signorini</name>
</author>
<author><name sortKey="Liew, Steven" sort="Liew, Steven" uniqKey="Liew S" first="Steven" last="Liew">Steven Liew</name>
</author>
<author><name sortKey="Trindade De Almeida, Ada R" sort="Trindade De Almeida, Ada R" uniqKey="Trindade De Almeida A" first="Ada R" last="Trindade De Almeida">Ada R. Trindade De Almeida</name>
</author>
<author><name sortKey="Wu, Yan" sort="Wu, Yan" uniqKey="Wu Y" first="Yan" last="Wu">Yan Wu</name>
</author>
<author><name sortKey="Vieira Braz, Andre" sort="Vieira Braz, Andre" uniqKey="Vieira Braz A" first="André" last="Vieira Braz">André Vieira Braz</name>
</author>
<author><name sortKey="Fagien, Steven" sort="Fagien, Steven" uniqKey="Fagien S" first="Steven" last="Fagien">Steven Fagien</name>
</author>
<author><name sortKey="Goodman, Greg J" sort="Goodman, Greg J" uniqKey="Goodman G" first="Greg J" last="Goodman">Greg J. Goodman</name>
</author>
<author><name sortKey="Monheit, Gary" sort="Monheit, Gary" uniqKey="Monheit G" first="Gary" last="Monheit">Gary Monheit</name>
</author>
<author><name sortKey="Raspaldo, Herve" sort="Raspaldo, Herve" uniqKey="Raspaldo H" first="Hervé" last="Raspaldo">Hervé Raspaldo</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:26910696</idno>
<idno type="pmid">26910696</idno>
<idno type="doi">10.1097/01.prs.0000475758.63709.23</idno>
<idno type="wicri:Area/PubMed/Corpus">002124</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002124</idno>
<idno type="wicri:Area/PubMed/Curation">002098</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002098</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Global Aesthetics Consensus: Botulinum Toxin Type A--Evidence-Based Review, Emerging Concepts, and Consensus Recommendations for Aesthetic Use, Including Updates on Complications.</title>
<author><name sortKey="Sundaram, Hema" sort="Sundaram, Hema" uniqKey="Sundaram H" first="Hema" last="Sundaram">Hema Sundaram</name>
<affiliation wicri:level="1"><nlm:affiliation>Rockville, Md.; Milan, Italy; Sydney, New South Wales, and Carlton, Victoria, Australia; São Paolo and Rio de Janeiro, Brazil; Beijing, China; Boca Raton, Fla.; Seoul, Korea; and Cannes, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Rockville, Md.; Milan, Italy; Sydney, New South Wales, and Carlton, Victoria, Australia; São Paolo and Rio de Janeiro, Brazil; Beijing, China; Boca Raton, Fla.; Seoul, Korea; and Cannes</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Signorini, Massimo" sort="Signorini, Massimo" uniqKey="Signorini M" first="Massimo" last="Signorini">Massimo Signorini</name>
</author>
<author><name sortKey="Liew, Steven" sort="Liew, Steven" uniqKey="Liew S" first="Steven" last="Liew">Steven Liew</name>
</author>
<author><name sortKey="Trindade De Almeida, Ada R" sort="Trindade De Almeida, Ada R" uniqKey="Trindade De Almeida A" first="Ada R" last="Trindade De Almeida">Ada R. Trindade De Almeida</name>
</author>
<author><name sortKey="Wu, Yan" sort="Wu, Yan" uniqKey="Wu Y" first="Yan" last="Wu">Yan Wu</name>
</author>
<author><name sortKey="Vieira Braz, Andre" sort="Vieira Braz, Andre" uniqKey="Vieira Braz A" first="André" last="Vieira Braz">André Vieira Braz</name>
</author>
<author><name sortKey="Fagien, Steven" sort="Fagien, Steven" uniqKey="Fagien S" first="Steven" last="Fagien">Steven Fagien</name>
</author>
<author><name sortKey="Goodman, Greg J" sort="Goodman, Greg J" uniqKey="Goodman G" first="Greg J" last="Goodman">Greg J. Goodman</name>
</author>
<author><name sortKey="Monheit, Gary" sort="Monheit, Gary" uniqKey="Monheit G" first="Gary" last="Monheit">Gary Monheit</name>
</author>
<author><name sortKey="Raspaldo, Herve" sort="Raspaldo, Herve" uniqKey="Raspaldo H" first="Hervé" last="Raspaldo">Hervé Raspaldo</name>
</author>
</analytic>
<series><title level="j">Plastic and reconstructive surgery</title>
<idno type="eISSN">1529-4242</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors</term>
<term>Aged</term>
<term>Botulinum Toxins, Type A (adverse effects)</term>
<term>Botulinum Toxins, Type A (therapeutic use)</term>
<term>Consensus</term>
<term>Cosmetic Techniques (standards)</term>
<term>Evidence-Based Medicine</term>
<term>Female</term>
<term>Humans</term>
<term>Injections, Subcutaneous</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neurotoxins (administration & dosage)</term>
<term>Neurotoxins (adverse effects)</term>
<term>Patient Satisfaction (statistics & numerical data)</term>
<term>Practice Guidelines as Topic</term>
<term>Rejuvenation (physiology)</term>
<term>Risk Assessment</term>
<term>Skin Aging (drug effects)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Consensus</term>
<term>Facteurs de l'âge</term>
<term>Femelle</term>
<term>Guides de bonnes pratiques cliniques comme sujet</term>
<term>Humains</term>
<term>Injections sous-cutanées</term>
<term>Mâle</term>
<term>Médecine factuelle</term>
<term>Neurotoxines (administration et posologie)</term>
<term>Neurotoxines (effets indésirables)</term>
<term>Rajeunissement (physiologie)</term>
<term>Résultat thérapeutique</term>
<term>Satisfaction du patient ()</term>
<term>Sujet âgé</term>
<term>Techniques cosmétiques (normes)</term>
<term>Toxines botuliniques de type A (effets indésirables)</term>
<term>Toxines botuliniques de type A (usage thérapeutique)</term>
<term>Vieillissement de la peau ()</term>
<term>Évaluation des risques</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Neurotoxins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Botulinum Toxins, Type A</term>
<term>Neurotoxins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins, Type A</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Neurotoxines</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Skin Aging</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Neurotoxines</term>
<term>Toxines botuliniques de type A</term>
</keywords>
<keywords scheme="MESH" qualifier="normes" xml:lang="fr"><term>Techniques cosmétiques</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Rajeunissement</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Rejuvenation</term>
</keywords>
<keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Cosmetic Techniques</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Patient Satisfaction</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Toxines botuliniques de type A</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Age Factors</term>
<term>Aged</term>
<term>Consensus</term>
<term>Evidence-Based Medicine</term>
<term>Female</term>
<term>Humans</term>
<term>Injections, Subcutaneous</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Practice Guidelines as Topic</term>
<term>Risk Assessment</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Consensus</term>
<term>Facteurs de l'âge</term>
<term>Femelle</term>
<term>Guides de bonnes pratiques cliniques comme sujet</term>
<term>Humains</term>
<term>Injections sous-cutanées</term>
<term>Mâle</term>
<term>Médecine factuelle</term>
<term>Résultat thérapeutique</term>
<term>Satisfaction du patient</term>
<term>Sujet âgé</term>
<term>Vieillissement de la peau</term>
<term>Évaluation des risques</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Botulinum toxin type A injection remains the leading nonsurgical cosmetic procedure worldwide, with a high rate of efficacy and patient satisfaction.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26910696</PMID>
<DateCreated><Year>2016</Year>
<Month>02</Month>
<Day>25</Day>
</DateCreated>
<DateCompleted><Year>2016</Year>
<Month>07</Month>
<Day>08</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>09</Month>
<Day>08</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-4242</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>137</Volume>
<Issue>3</Issue>
<PubDate><Year>2016</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Plastic and reconstructive surgery</Title>
<ISOAbbreviation>Plast. Reconstr. Surg.</ISOAbbreviation>
</Journal>
<ArticleTitle>Global Aesthetics Consensus: Botulinum Toxin Type A--Evidence-Based Review, Emerging Concepts, and Consensus Recommendations for Aesthetic Use, Including Updates on Complications.</ArticleTitle>
<Pagination><MedlinePgn>518e-529e</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/01.prs.0000475758.63709.23</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Botulinum toxin type A injection remains the leading nonsurgical cosmetic procedure worldwide, with a high rate of efficacy and patient satisfaction.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">A multinational, multidisciplinary group of plastic surgeons and dermatologists convened the Global Aesthetics Consensus Group to develop updated consensus recommendations with a worldwide perspective for botulinum toxin and hyaluronic acid fillers. This publication on botulinum toxin type A considers advances in facial analysis, injection techniques, and avoidance and management of complications.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Use of botulinum toxin has evolved from the upper face to also encompass the lower face, neck, and midface. The Global Aesthetics Consensus Group emphasizes an integrative, diagnostic approach. Injection dosage and placement are based on analysis of target muscles in the context of adjacent ones and associated soft and hard tissues. The indication for selection of botulinum toxin as a primary intervention is that excessive muscular contraction is the primary etiology of the facial disharmony to be addressed. Global Aesthetics Consensus Group recommendations demonstrate a paradigm shift toward neuromodulation rather than paralysis, including lower dosing of the upper face, more frequent combination treatment with hyaluronic acid fillers, and intracutaneous injection where indicated to limit depth and degree of action.</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The accumulation of clinical evidence and experience with botulinum toxin has led to refinements in treatment planning and implementation. The Global Aesthetics Consensus Group advocates an etiology-driven, patient-tailored approach, to enable achievement of optimal efficacy and safety in patient populations that are rapidly diversifying with respect to ethnicity, gender, and age.</AbstractText>
<AbstractText Label="CLINICAL QUESTION/LEVEL OF EVIDENCE" NlmCategory="METHODS">Therapeutic, V.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sundaram</LastName>
<ForeName>Hema</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Rockville, Md.; Milan, Italy; Sydney, New South Wales, and Carlton, Victoria, Australia; São Paolo and Rio de Janeiro, Brazil; Beijing, China; Boca Raton, Fla.; Seoul, Korea; and Cannes, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Signorini</LastName>
<ForeName>Massimo</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Liew</LastName>
<ForeName>Steven</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Trindade de Almeida</LastName>
<ForeName>Ada R</ForeName>
<Initials>AR</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wu</LastName>
<ForeName>Yan</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Vieira Braz</LastName>
<ForeName>André</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Fagien</LastName>
<ForeName>Steven</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Goodman</LastName>
<ForeName>Greg J</ForeName>
<Initials>GJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Monheit</LastName>
<ForeName>Gary</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>Raspaldo</LastName>
<ForeName>Hervé</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><CollectiveName>Global Aesthetics Consensus Group</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Plast Reconstr Surg</MedlineTA>
<NlmUniqueID>1306050</NlmUniqueID>
<ISSNLinking>0032-1052</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009498">Neurotoxins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.24.69</RegistryNumber>
<NameOfSubstance UI="D019274">Botulinum Toxins, Type A</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Clin Plast Surg. 2008 Jul;35(3):319-27; discussion 317</RefSource>
<PMID Version="1">18558224</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Cosmet Dermatol. 2011 Mar;10(1):36-50</RefSource>
<PMID Version="1">21332914</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Acad Dermatol. 2013 Mar;68(3):353.e1-8</RefSource>
<PMID Version="1">23394923</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Acad Dermatol. 2006 Aug;55(2):272-5</RefSource>
<PMID Version="1">16844511</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Plast Reconstr Surg. 2010 Jan;125(1):332-42</RefSource>
<PMID Version="1">20048624</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dermatol Surg. 2012 Sep;38(9):1506-15</RefSource>
<PMID Version="1">22804914</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Cosmet Dermatol. 2011 Jun;10(2):131-49</RefSource>
<PMID Version="1">21649819</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Facial Plast Surg Clin North Am. 2007 Aug;15(3):283-91, v</RefSource>
<PMID Version="1">17658424</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dermatol Surg. 2005 Mar;31(3):271-5</RefSource>
<PMID Version="1">15841625</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dermatol Ther (Heidelb). 2013 Dec;3(2):179-89</RefSource>
<PMID Version="1">24318416</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Dermatolog Treat. 2013 Apr;24(2):133-6</RefSource>
<PMID Version="1">21888570</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dermatol Surg. 2003 Sep;29(9):943-50; discussion 950-1</RefSource>
<PMID Version="1">12930337</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dermatol Surg. 2005 Aug;31(8 Pt 1):923-7</RefSource>
<PMID Version="1">16042937</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Aesthet Surg J. 2012 Jan;32(1):96-102</RefSource>
<PMID Version="1">22231417</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dermatol Surg. 2001 Aug;27(8):703-8</RefSource>
<PMID Version="1">11493292</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Orthod Dentofacial Orthop. 2008 Feb;133(2):195-203</RefSource>
<PMID Version="1">18249285</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Plast Reconstr Surg. 2016 May;137(5):1410-23</RefSource>
<PMID Version="1">27119917</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dermatol Surg. 2007 Jan;33(1 Spec No.):S10-7</RefSource>
<PMID Version="1">17241408</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dermatol Surg. 2008 Nov;34 Suppl 2:S173-8</RefSource>
<PMID Version="1">19021676</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dermatol Surg. 2014 May;40(5):525-36</RefSource>
<PMID Version="1">24575858</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Plast Reconstr Surg. 2008 May;121(5 Suppl):5S-30S; quiz 31S-36S</RefSource>
<PMID Version="1">18449026</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dermatol Surg. 2008 Jun;34 Suppl 1:S85-91; discussion S91</RefSource>
<PMID Version="1">18547187</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dermatol Surg. 2014 Nov;40(11):1181-90</RefSource>
<PMID Version="1">25347451</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dermatol Surg. 2013 Mar;39(3 Pt 2):510-25</RefSource>
<PMID Version="1">23458295</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dermatol Surg. 2015 Jan;41 Suppl 1:S88-92</RefSource>
<PMID Version="1">25548851</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dermatol Surg. 2015 Jan;41(1):102-12</RefSource>
<PMID Version="1">25485803</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dermatol Surg. 2012 Sep;38(9):1497-505</RefSource>
<PMID Version="1">22621180</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Dermatol. 2002 Apr;138(4):510-4</RefSource>
<PMID Version="1">11939813</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Forensic Sci Int. 2007 Oct 2;172(1):1-9</RefSource>
<PMID Version="1">17434276</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dermatol Surg. 2015 Jan;41 Suppl 1:S19-28</RefSource>
<PMID Version="1">25548841</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Aesthet Surg J. 2006 Jan-Feb;26(1S):S4-9</RefSource>
<PMID Version="1">19338976</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Acad Dermatol. 2009 Dec;61(6):961-70.e1-11</RefSource>
<PMID Version="1">19744746</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dermatol Surg. 2003 May;29(5):523-9; discussion 529</RefSource>
<PMID Version="1">12752522</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Plast Reconstr Surg. 2007 Oct;120(5):1367-76; discussion 1377</RefSource>
<PMID Version="1">17898614</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Plast Reconstr Surg. 1999 Feb;103(2):635-44</RefSource>
<PMID Version="1">9950555</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dermatol Surg. 2010 Dec;36 Suppl 4:2168-71</RefSource>
<PMID Version="1">21134048</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Acad Dermatol. 2013 Mar;68(3):364.e1-10</RefSource>
<PMID Version="1">23394924</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Curr Med Res Opin. 2004 Jul;20(7):981-90</RefSource>
<PMID Version="1">15265242</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pharmacotherapy. 2013 Mar;33(3):304-18</RefSource>
<PMID Version="1">23400888</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dermatol Surg. 2010 Dec;36 Suppl 4:2121-34</RefSource>
<PMID Version="1">21134044</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Plast Reconstr Surg. 2003 Oct;112(5 Suppl):33S-39S</RefSource>
<PMID Version="1">14504483</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dermatol Surg. 2011 Nov;37(11):1553-65</RefSource>
<PMID Version="1">21777338</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Drugs Dermatol. 2013 Aug;12(8):932-7</RefSource>
<PMID Version="1">23986168</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Angle Orthod. 2009 Jan;79(1):70-7</RefSource>
<PMID Version="1">19123705</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Cosmet Investig Dermatol. 2012;5:23-31</RefSource>
<PMID Version="1">22291477</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dermatol Surg. 2012 Nov;38(11):1794-803</RefSource>
<PMID Version="1">23106853</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dermatol Surg. 2015 Mar;41(3):321-6</RefSource>
<PMID Version="1">25705950</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Aesthetic Plast Surg. 2012 Oct;36(5):1211-5</RefSource>
<PMID Version="1">22692787</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Drugs Dermatol. 2012 Sep;11(9):1041-5</RefSource>
<PMID Version="1">23135645</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dermatol Surg. 2010 Nov;36 Suppl 3:1852-8</RefSource>
<PMID Version="1">20969662</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dermatol Surg. 2015 Apr;41(4):447-56</RefSource>
<PMID Version="1">25789814</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Aesthetic Plast Surg. 2012 Aug;36(4):753-60</RefSource>
<PMID Version="1">22580543</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019274" MajorTopicYN="N">Botulinum Toxins, Type A</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D032921" MajorTopicYN="N">Consensus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003357" MajorTopicYN="N">Cosmetic Techniques</DescriptorName>
<QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007279" MajorTopicYN="N">Injections, Subcutaneous</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009498" MajorTopicYN="N">Neurotoxins</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017410" MajorTopicYN="Y">Practice Guidelines as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012060" MajorTopicYN="N">Rejuvenation</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015595" MajorTopicYN="N">Skin Aging</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<InvestigatorList><Investigator ValidYN="Y"><LastName>Braz</LastName>
<ForeName>André Vieira</ForeName>
<Initials>AV</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Carruthers</LastName>
<ForeName>Jean D A</ForeName>
<Initials>JD</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>De Boulle</LastName>
<ForeName>Koenraad L</ForeName>
<Initials>KL</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Fagien</LastName>
<ForeName>Steven</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Goodman</LastName>
<ForeName>GregJ</ForeName>
<Initials>G</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Lee</LastName>
<ForeName>Soo-Keun</ForeName>
<Initials>SK</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Liew</LastName>
<ForeName>Steven</ForeName>
<Initials>S</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Monheit</LastName>
<ForeName>Gary</ForeName>
<Initials>G</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Raspaldo</LastName>
<ForeName>Hervé</ForeName>
<Initials>H</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Rohrich</LastName>
<ForeName>Rod</ForeName>
<Initials>R</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Sattler</LastName>
<ForeName>Gerhard</ForeName>
<Initials>G</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Signorini</LastName>
<ForeName>Massimo</ForeName>
<Initials>M</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Sundaram</LastName>
<ForeName>Hema</ForeName>
<Initials>H</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Swift</LastName>
<ForeName>Arthur</ForeName>
<Initials>A</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Trindade de Almeida</LastName>
<ForeName>Ada R</ForeName>
<Initials>AR</Initials>
</Investigator>
<Investigator ValidYN="Y"><LastName>Wu</LastName>
<ForeName>Yan</ForeName>
<Initials>Y</Initials>
</Investigator>
</InvestigatorList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>2</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>2</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>7</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26910696</ArticleId>
<ArticleId IdType="doi">10.1097/01.prs.0000475758.63709.23</ArticleId>
<ArticleId IdType="pii">00006534-201603000-00010</ArticleId>
<ArticleId IdType="pmc">PMC5242214</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002098 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002098 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:26910696 |texte= Global Aesthetics Consensus: Botulinum Toxin Type A--Evidence-Based Review, Emerging Concepts, and Consensus Recommendations for Aesthetic Use, Including Updates on Complications. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:26910696" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |